Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: Results of a multicenter, phase III, randomized, double-blind, placebo-controlled study

Japanese Journal of Clinical Oncology

Volumn 39, Issue 3, 2009, Pages 163-168

  Tsuboi, Masahiro ^a   Ezaki, Kohji ^b   Tobinai, Kensei ^c   Ohashi, Yasuo ^d   Saijo, Nagahiro ^e  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Anemia; Cancer; Chemotherapy induced anemia; Erythropoietin; Quality of life; Survival

Indexed keywords

ANTHRACYCLINE; HEMOGLOBIN; PLATINUM DERIVATIVE; RECOMBINANT ERYTHROPOIETIN; TAXANE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD PRESSURE; BRAIN INFARCTION; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FATIGUE; FEMALE; GLUCOSE URINE LEVEL; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; LUNG CANCER; LYMPHOCYTOPENIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PARTIAL THROMBOPLASTIN TIME; PHASE 3 CLINICAL TRIAL; PURE RED CELL ANEMIA; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTOPENIA;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 61449167041     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn151     Document Type: Article

References (25)

1. Beguin Y. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Haematologica 2002;87:1209-21.
2. Littlewood TJ. Effects of epoetin alfa on hematologic parameters and in quality of life in cancer patients receiving nonplatinum chemotherapy. J Clin Oncol 2001;19:2865-74.
3. Gabrilove JL, Cleeland CS, Livingston RB, Sarokhan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875-82.
4. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412-25.
5. Iconomou G, Koutras A, Rigopoulos A, Vagenakis AG, Kalofonos HP. Effect of recombinant human erythropoietin on quality of life in cancer patients receiving chemotherapy: Results of a randomized, controlled trial. J Pain Symptom Manage 2003;25:512-8.
6. Osterborg A, Brandberg Y, Molostova V, Iosava G, Abdulkadyrov K, Hedenus M, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486-94.
7. Lind M, Vernon C, Cruickshank D, Wilkinson P, Littlewood T, Stuart N, et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer 2002;86:1243-9.
8. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, et al. Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-107.
9. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 2005;23:5960-72.
10. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: Randomized, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
11. Henke M, Mattern D, Pepe M, Bezay C, Weissenberger C, Werner M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-13.
12. Danish Head and Neck Cancer Group. Interim analysis of DAHANCA10: Study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck. Available from: http://www.dahanca.dk/get_media_file.php?mediaid=125.
13. Wright JR, Ung YC, Julian JA, Pritchard KI, Whelan TJ, Smith C, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-32.
14. Smith RE, Jr, Aapro MS, Ludwig H, Pinter T, Smakal M, Tudor E, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-50.
15. Thomas G, Ali S, Hoebers FJP, Darcy KM, Rodgers WH, Patel M, et al. Phase III trial to evaluate the efficacy of maintaing hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317-25.
16. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-24.
17. FDA ALERT. Information on Erythropoiesis Stimulating Agents (ESA). Available from: http://www.fda.gov/cder/drug/InfoSheets/HCP/ RHE2007HCP.htm (Updated on 2007 March 09; cited on 2006 November 16).
18. Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update. Blood 2008;111:25-41.
19. Morishima Y, Ogura M, Yoneda S, Sakai H, Tobinai K, Nishiwaki Y, et al. Qnce-weekly epoetin-beta improves hemoglobin levels in cancer patients with chemotherapy-induced anemia: A randomized, double-blind, dose-finding study. Jpn J Clin Oncol. 2006;36:655-61.
20. Staguet MJ, Hays RD, Fayers PM. Quality of life assessment in clinical trials. Oxford: Oxford University Press 1998,306-14.
21. Hedenus M, Adriansson M, San Miguel J, Kramer MH, Schipperus MR, Juvonen E, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403.
22. Spano JP, Khayat D. Treatment Options for anemia, taking risks into consideration: Erythropoiesis-stimulating agents versus transfusions. The Oncologist 2008;13:27-32.
23. Abels RI, Larholt KM, Krantz KD, Bryant EC. Recombinat human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist 1996;1:140-50.
24. Savonije JH, van Groeningen CJ, van Bochove A, Honkoop AH, van Felius CL, Wormhoudt LW, et al. Effects of early intervention with epoetin alfa on requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial. Eur J Cancer 2005;41:1560-9.
25. Witzig TE, Silberstein PT, Loprinzi CL, Sloan JA, Novotny PJ, Mailliard JA, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2005;23:2606-17.